Overview
- Under the agreement, Eli Lilly will manufacture and supply tirzepatide and Cipla will distribute and promote it nationwide under the Yurpeak brand.
- Yurpeak will match Mounjaro’s pricing, with company-stated MRPs of ₹3,500 for 2.5 mg vials and ₹4,375 for 5 mg, and will also be available as a once‑weekly KwikPen.
- The product will be offered in six strengths from 2.5 mg to 15 mg in a multi‑dose prefilled pen that delivers four weekly doses to support individualized titration.
- Mounjaro, launched in March, quickly scaled to India’s No. 2 selling drug by September with ₹80 crore for the month and ₹233 crore in sales through September.
- Analysts expect fiercer competition next year as semaglutide’s primary patent in India expires in March 2026, a shift that could open the market to lower‑cost generics.